Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06986161 · ClinicalTrials.gov registry record · NA
Optimizing Mango's Glycemic Impact: Investigating Mango Consumption Timing in Prediabetic Individuals
A NA study of PreDiabetes, sponsored by Clinical Nutrition Research Center, Illinois Institute of Technology.
- Recruiting
- Registry status
- NA
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT06986161: Recruiting NA study of PreDiabetes, sponsored by Clinical Nutrition Research Center, Illinois Institute of Technology.
NCT06986161 is a NA study of PreDiabetes that is actively recruiting participants, run by Clinical Nutrition Research Center, Illinois Institute of Technology. The registered enrollment target is 30 participants, below the 701-participant average among 149 other PreDiabetes trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06986161, a NA study of PreDiabetes, is actively recruiting participants, sponsored by Clinical Nutrition Research Center, Illinois Institute of Technology.
- RECRUITING
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to investigate the effect of mango intake on metabolic and inflammatory responses relative to meals in individuals at risk of developing diabetes, as well as to understand how the beneficial compounds found in mangoes are absorbed and processed in the body.
Primary Outcome
Change in postprandial glucose as measured by absolute values and calculated insulin sensitivity using homeostasis model assessment of fasting insulin sensitivity (HOMA-%S) and B-cell function (HOMA-%).
Conditions Studied
Interventions
- OTHER Mango
- OTHER Control Beverage
Study Locations (1)
Illinois
- Clinical Nutrition Research Center - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2025-04-14 |
| Est. Completion | 2026-12-31 |
| Phase | NA |
What NCT06986161 shows while recruiting
NCT06986161 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 701-participant average among 149 other PreDiabetes trials with a reported enrollment target (96% lower).
The record links to 1 condition, with PreDiabetes appearing as the primary indexed condition, and to 2 interventions - of which Mango is the first listed.
NCT06986161 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT06986161 about?
NCT06986161 is a clinical study titled "Optimizing Mango's Glycemic Impact: Investigating Mango Consumption Timing in Prediabetic Individuals". The purpose of this study is to investigate the effect of mango intake on metabolic and inflammatory responses relative to meals in individuals at risk of developing diabetes, as well as to understand how the beneficial compounds found in mangoes are absorbed and processed in the body.
What is the current status of trial NCT06986161?
This trial is currently recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2025-04-14. Estimated completion is 2026-12-31.
What conditions does trial NCT06986161 study?
This clinical trial studies the following conditions: PreDiabetes.
What interventions are being tested in trial NCT06986161?
The interventions under investigation include: Mango (OTHER), Control Beverage (OTHER).
Who is sponsoring clinical trial NCT06986161?
This trial is sponsored by Clinical Nutrition Research Center, Illinois Institute of Technology, which has 59 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06986161 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for PreDiabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06986161's enrollment target sits among peer trials
30 118th of 149 higher than 23 of 149 other PreDiabetes trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other PreDiabetes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Longitudinal Multi-Omic Profiles to Reveal Mechanisms of Obesity-Mediated Insulin Resistance
RECRUITING · NA
-
Black Impact: The Mechanisms Underlying Psychosocial Stress Reduction in a Cardiovascular Health Intervention
RECRUITING · NA
-
Diabetes Clinical Decision Support
RECRUITING · NA
-
Food as Medicine for HIV and Diabetes
RECRUITING · NA
-
Cleaner Air for Lower Cardiometabolic Risk
RECRUITING · NA
-
Strategies for Implementing a Postpartum Lifestyle Intervention in WIC Clinics
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI